commonli
use
antiretrovir
drug
human
veterinari
medicin
rti
three
categori
rti
nucleosid
analogu
rti
narti
section
nucleotid
analogu
rti
section
nonnucleosid
rti
nnrti
section
nucleosid
consist
nitrogen
base
coval
attach
sugar
ribos
rna
dna
nucleotid
consist
nitrogen
base
sugar
phosphat
group
nucleic
acid
rna
dna
contain
chain
nucleotid
coval
link
form
sugarphosph
backbon
protrud
nitrogen
base
prior
linkag
new
nucleotid
monophosph
nucleic
acid
three
phosphat
group
must
bound
nucleosid
triphosph
two
remov
releas
energi
elong
nucleic
acid
chain
zidovudin
azt
first
synthes
potenti
anticanc
drug
shown
effect
hiv
becam
first
drug
approv
treatment
hiv
infect
antifiv
activ
zidovudin
assess
numer
vitro
studi
differ
cell
system
first
vitro
studi
carri
north
cowork
show
zidovudin
inhibit
fiv
replic
crandellre
felin
kidney
crfk
cell
suscept
fiv
zidovudin
similar
hiv
evid
fiv
becom
resist
nucleosid
analogu
case
hiv
zidovudineresist
fiv
mutant
aris
six
month
use
singlepoint
mutat
fiv
gene
respons
resist
vivo
zidovudin
reduc
plasma
viral
load
improv
immunolog
clinic
statu
fivinfect
cat
increas
qualiti
life
prolong
life
expect
placebocontrol
trial
zidovudin
improv
stomat
increas
ratio
natur
fivinfect
cat
cat
fivassoci
neurolog
sign
mark
improv
report
within
first
day
therapi
zidovudin
inhibit
rt
also
cellular
polymeras
lead
bone
marrow
suppress
regular
blood
cell
count
necessari
zidovudin
treatment
nonregen
anemia
common
side
effect
cat
bone
marrow
suppress
treat
zidovudin
fivinfect
cat
treat
zidovudin
long
two
year
toler
drug
well
hematocrit
declin
within
three
week
initi
treatment
approxim
baselin
increas
afterward
case
even
without
discontinu
treatment
hematocrit
drop
discontinu
treatment
recommend
anemia
usual
resolv
within
day
side
effect
cat
includ
vomit
anorexia
rare
stavudin
anoth
drug
effect
hiv
approv
treatment
hiv
infect
recent
year
replac
multidrug
treatment
protocol
compound
fewer
side
effect
stavudin
activ
fiv
vitro
mutant
fiv
resist
stavudin
crossresist
sever
antivir
includ
zidovudin
detect
resist
caus
singlepoint
mutat
rtencod
region
pol
gene
vivo
data
fivinfect
cat
publish
didanosin
ddl
shown
activ
hiv
unit
state
second
drug
approv
treatment
hiv
market
sinc
didanosin
activ
fiv
vitro
one
experiment
vivo
studi
fiv
replic
significantli
suppress
anim
treat
didanosin
treatment
contribut
develop
antiretrovir
toxic
neuropathi
lamivudin
also
antihiv
drug
approv
lamivudin
activ
fiv
vitro
combin
zidovudin
lamivudin
synergist
antifiv
activ
cell
cultur
fiv
mutant
resist
lamivudin
contain
point
mutat
rt
gene
select
vitro
show
cross
resist
zidovudin
one
vivo
studi
experiment
fivinfect
cat
treat
highdos
zidovudinelamivudin
combin
protect
cat
infect
treatment
start
viru
inocul
howev
zidovudinelamivudin
treatment
show
antifiv
activ
chronic
infect
cat
sever
side
effect
includ
fever
anorexia
mark
hematolog
chang
observ
cat
highdos
dualdrug
treatment
thu
highdos
lamivudin
treatment
alon
combin
zidovudin
recommend
natur
fivinfect
cat
emtricitabin
ftc
structur
similar
lamivudin
licens
fda
vitro
antivir
efficaci
demonstr
fiv
date
vivo
studi
fivinfect
cat
abacavir
cyclopropylamino
abc
shown
activ
hiv
belong
fdaapprov
antihiv
compound
abacavir
activ
fiv
vitro
higher
level
cytotox
compound
didanosin
amdoxovir
vivo
studi
drug
fivinfect
cat
adefovir
ethoxymethylphosphon
acid
pmea
activ
herpesvirus
hepadnavirus
hepat
b
retrovirus
adefovir
licens
hiv
drug
current
avail
oral
formul
bispom
pmea
approv
treatment
chronic
hepat
b
adefovir
belong
acycl
nucleosid
phosphon
alkyl
side
chain
purin
pyrimidin
link
modifi
phosphat
moieti
cp
phosphon
linkag
replac
normal
phosphat
linkag
phosphon
bond
hydrolys
make
difficult
cleav
compound
incorpor
end
elong
provir
dna
strand
adefovir
inhibit
fiv
replic
vitro
sever
studi
investig
efficaci
adefovir
either
experiment
natur
fivinfect
cat
studi
show
efficaci
also
report
sever
side
effect
mainli
nonregen
anemia
recent
studi
adefovir
administ
fivinfect
cat
sixweek
placebocontrol
doubleblind
clinic
trial
ten
cat
receiv
adefovir
mgkg
sc
twice
weekli
ten
cat
receiv
placebo
decreas
provir
viral
load
treat
cat
treat
cat
develop
progress
sometim
lifethreaten
anemia
common
advers
effect
ntarti
show
result
obtain
experiment
studi
alway
appli
field
situat
emphas
import
control
clinic
field
trial
base
lack
efficaci
recent
placebocontrol
field
trial
side
effect
adefovir
recommend
treatment
fivinfect
cat
current
approv
ntarti
treatment
hiv
infect
tenofovir
disoproxil
fumar
tdf
prodrug
tenofovir
r
adenin
r
pmpa
also
member
acycl
nucleosid
phosphon
antivir
spectrum
tenofovir
acid
pmpa
narrow
adefovir
encompass
herpesvirus
confin
hepadna
retrovirus
tenofovir
disoproxil
fumar
becom
one
commonli
use
drug
hiv
therapi
sinc
licens
tenofovir
effect
fiv
vitro
evid
tenovovir
might
greater
antifiv
efficaci
less
cytotox
antiretrovir
compound
includ
adefovir
howev
vivo
studi
lack
focu
futur
research
suramin
naphthalen
acid
sodium
salt
sulfat
naphthylamin
trypan
red
deriv
one
oldest
known
antimicrobi
agent
use
antitrypanosom
agent
treatment
tumor
prostat
cancer
also
inhibitori
effect
rt
activ
retrovirus
also
use
human
hiv
infect
suramin
inhibit
rt
interact
templateprim
bind
site
enzym
thu
competit
bind
primer
bind
site
without
nucleosid
analogu
inhibit
templateprim
bind
necessari
dna
elong
suramin
therefor
classifi
nnrti
suramin
effect
felin
leukemia
viru
felv
vivo
thu
could
potenti
activ
fiv
although
investig
suramin
associ
signific
number
sever
side
effect
human
nausea
anaphylact
shock
immedi
reaction
administr
peripher
neuriti
lead
palmarplantar
hyperesthesia
photophobia
skin
reaction
agranulocytosi
hemolyt
anemia
destruct
adren
cortex
later
side
effect
cat
felv
infect
major
advers
effect
suramin
transient
vomit
anorexia
foscarnet
phosphonoform
acid
pfa
broadspectrum
antivir
activ
dna
rna
virus
includ
retrovirus
fdaapprov
treatment
hivassoci
cytomegalo
herp
simplex
viru
infect
human
foscarnet
usual
administ
intraven
continu
intraven
infus
short
halflif
also
demonstr
cat
oral
administr
drug
possibl
result
irrit
mucou
membran
oral
bleed
foscarnet
mani
side
effect
includ
nephrotox
myelosuppress
human
cat
also
toxic
epitheli
cell
mucou
membran
result
gastrointestin
side
effect
genit
epithelium
ulcer
addit
chelat
variou
cation
lead
hypocalcemia
hypomagnesemia
hypokalemia
vitro
foscarnet
shown
activ
fiv
foscarnetresist
fiv
strain
develop
vivo
studi
fivinfect
cat
carri
like
sever
side
effect
necess
continu
intraven
administr
drug
ribavirin
rtca
mark
vitro
antivir
activ
varieti
dna
rna
virus
system
administr
ribavirin
limit
cat
side
effect
sequestr
ribavirin
within
erythrocyt
result
hemolysi
even
low
dose
drug
use
addit
doserel
toxic
effect
bone
marrow
primarili
megakaryocyt
result
thrombocytopenia
hemorrhag
prolong
ribavirin
treatment
higher
dose
product
erythrocyt
neutrophil
also
suppress
ribavirin
also
induc
hepat
toxic
attempt
decreas
toxic
ribavirin
incorpor
lecithincontain
liposom
administ
lower
dose
success
ribavirin
activ
mani
virus
vitro
includ
fiv
therapeut
concentr
difficult
achiev
vivo
toxic
date
efficaci
ribavirin
investig
fivinfect
cat
plerixafor
bi
octachlorid
dehydr
bicyclam
prototyp
compound
market
antihiv
drug
use
human
stem
cell
mobil
plerixafor
activ
fiv
vitro
placebocontrol
doubleblind
clinic
trial
treatment
natur
fivinfect
cat
plerixafor
result
signific
decreas
provir
load
treat
cat
compar
placebo
group
concomit
decreas
serum
magnesium
level
produc
clinic
consequ
develop
resist
fiv
isol
plerixafor
occur
treatment
cat
plerixafor
administ
dosag
mgkg
everi
h
monitor
magnesium
calcium
level
perform
regular
interv
treatment
studi
investig
potenti
promis
drug
need
tipranavir
n
propi
l
phenyl
trifluoromethyl
approv
use
antihiv
compound
drug
shown
activ
fiv
vitrotipranavir
complet
prevent
fiv
replic
studi
fivinfect
cat
exist
far
studi
need
investig
potenti
tipranavir
natur
infect
cat
lopinavir
n
acetamido
butanamid
antihiv
compound
approv
drug
shown
activ
fiv
vitro
prevent
fiv
replic
complet
vivo
studi
fivinfect
cat
atazanavir
methyl
n
methoxycarbonylamino
amino
butyl
methyl
hydrazinyl
carbam
licens
fda
also
use
antihiv
compound
similar
lopinavir
efficaci
atazanavir
shown
fiv
vitro
vivo
studi
publish
far
raltegravir
use
antihiv
compound
drug
shown
activ
fiv
vitro
fiv
less
suscept
raltegravir
hiv
studi
fivinfect
cat
exist
far
although
vivo
studi
efficaci
raltegravir
fivinfect
cat
drug
recent
shown
effect
felv
safe
cat
recombin
human
antivir
immunemodulatori
activ
activ
mani
dna
rna
virus
two
common
treatment
regimen
use
cat
sc
inject
ukg
everi
h
oral
applic
ukg
everi
h
human
becom
ineffect
three
seven
week
parenter
use
cat
product
neutral
antibodi
antibodi
product
occur
oral
administr
therefor
rout
allow
longer
period
treatment
inactiv
gastric
acid
destroy
trypsin
proteolyt
enzym
duodenum
mean
direct
antivir
effect
unlik
oral
applic
howev
oral
appear
immunomodulatori
activ
stimul
local
lymphoid
tissu
releas
cytokin
lymphat
cell
oropharyng
area
trigger
cascad
immunolog
respons
system
effect
shown
activ
fiv
vitro
although
frequent
use
field
treat
fivinfect
cat
control
studi
evalu
effect
parenter
administr
fivinfect
cat
conduct
use
oral
ill
natur
fivinfect
cat
ukg
appli
oral
mucosa
daili
seven
day
altern
week
six
month
follow
twomonth
break
repetit
sixmonth
treatment
result
improv
clinic
sign
eg
fever
lymphadenopathi
opportunist
infect
placebocontrol
doubleblind
studi
howev
provir
viral
load
monitor
thiat
studi
therefor
imposs
conclud
whether
treatment
rhuifn
inde
effect
fiv
rather
secondari
infect
recombin
felin
correspond
felin
interferon
licens
use
veterinari
medicin
japan
australia
european
countri
use
cat
long
period
without
antibodi
develop
major
sever
side
effect
report
inhibit
fiv
replic
vitro
one
placebocontrol
multicent
studi
investig
effect
parenter
fiv
infect
natur
fivinfect
cat
treat
ukg
sc
q
h
five
consecut
day
find
differ
surviv
rate
treat
cat
howev
improv
clinic
score
includ
eight
categori
clinic
sign
rectal
temperatur
behavior
appetit
thirst
dehydr
mucou
membran
appear
stomat
death
well
improv
laboratori
abnorm
leukopenia
leukocytosi
anemia
occur
anoth
studi
evalu
natur
fivinfect
cat
hous
shelter
clinic
improv
observ
parenter
ukg
sc
q
h
five
consecut
day
three
cycl
studi
lack
placebo
control
studi
hematolog
valu
remain
within
refer
interv
biochem
abnorm
associ
treatment
recent
studi
evalu
use
oral
administr
treatment
eleven
clientown
natur
fivinfect
cat
clinic
sign
treatment
protocol
ucat
po
q
h
consecut
day
administ
cat
owner
histor
retrospect
group
use
control
comparison
ukg
sc
q
h
five
consecut
day
three
cycl
placebo
group
includ
treatment
oral
result
signific
improv
clinic
score
eg
oral
lesion
coat
appear
bodi
condit
score
ocular
discharg
treatment
addit
signific
differ
sc
histor
control
group
po
group
suggest
oral
administr
might
viabl
less
expens
altern
recent
publish
studi
assess
viremia
proviru
load
blood
cytokin
profil
natur
fivinfect
cat
treat
oral
ucat
po
q
h
day
subcutan
ucat
sc
q
h
consecut
day
three
cours
chang
level
viremia
cytokin
level
found
placebo
control
group
includ
fact
viru
load
remain
unchang
clinic
improv
observ
earlier
studi
suggest
effect
secondari
infect
rather
fiv
major
differ
outcom
differ
studi
felin
fivinfect
cat
thu
definit
conclus
drawn
without
addit
random
placebocontrol
doubleblind
studi
includ
suffici
high
number
natur
fivinfect
cat
unfortun
efficaci
antivir
compound
treatment
fiv
cat
gener
poor
durat
treatment
mani
clinic
trial
rel
short
might
inadequ
infect
long
clinic
cours
addit
difficult
compar
treatment
result
cat
infect
experiment
kept
laboratori
condit
pet
cat
infect
field
strain
fiv
therefor
welldesign
doubleblind
placebocontrol
trial
use
antivir
drug
natur
fivinfect
cat
need
determin
efficaci
side
effect
differ
antivir
compound
